Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes
Open Access
- 14 February 2023
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (5) , 1351-1360
Abstract
Aims: To perform an integrated analysis of the safety and efficacy of dasiglucagon, a glucagon analogue available in a ready‐to‐use aqueous formulation, to treat severe hypoglycaemia (SH) in type 1 diabetes (T1D). Materials and Methods: An integrated analysis of dasiglucagon safety was conducted on data from two placebo‐controlled trials (placebo‐controlled pool) and two placebo‐controlled and four non‐placebo‐controlled trials (broad pool) in adults with T1D. An integrated analysis of dasiglucagon efficacy was conducted of pooled data and within demographic subgroups from the two placebo‐controlled and two non‐placebo‐controlled trials in adults with T1D. Results: Dasiglucagon had a similar safety and tolerability profile to that of reconstituted glucagon. In the placebo‐controlled datasets, no serious adverse events (AEs), AEs leading to withdrawal from the trial, or deaths were reported. The most common causally related AEs were nausea (56.5%) and vomiting (24.6%). The broad pool safety analysis showed similar results. Dasiglucagon efficacy in time to plasma glucose recovery from insulin‐induced SH was similar to that of reconstituted glucagon (median 10.0 and 12.0 minutes, respectively) and superior to placebo (median 40.0 minutes; P < 0.0001). The median recovery time was consistent across all placebo‐controlled trial subgroups. Conclusions: Dasiglucagon was well tolerated and effective as a rapid rescue agent for insulin‐induced SH in people with T1D.Keywords
This publication has 30 references indexed in Scilit:
- Faster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation StudyDiabetes Technology & Therapeutics, 2017
- Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin‐treated type 1 and type 2 diabetes: the global HAT studyDiabetes, Obesity and Metabolism, 2016
- Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 DiabetesDiabetes Care, 2016
- Hypoglycaemia in diabetes mellitus: epidemiology and clinical implicationsNature Reviews Endocrinology, 2014
- The Influence of New European Union Driver’s License Legislation on Reporting of Severe Hypoglycemia by Patients With Type 1 DiabetesDiabetes Care, 2014
- Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine SocietyDiabetes Care, 2013
- Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approachDiabetes, Metabolic Syndrome and Obesity, 2011
- Glucagon as a Treatment of Severe HypoglycemiaThe Diabetes Educator, 2008
- Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their durationDiabetologia, 2007
- Glucagon administration – underevaluated and undertaughtPractical Diabetes International, 2001